Pik3ca Mutation clinical trials

Explore recruiting pik3ca mutation clinical trials.

Recruiting pik3ca mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pik3ca Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A two-stage double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with a PIK3CA mutation

France, Italy, Germany, Spain, Belgium, Netherlands +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

Slovakia, Ireland, Bulgaria, Romania, Poland, Greece +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment with Inavolisib Combinations in Patients with Untreated, Early-Stage, PIK3CA-Mutated Breast Cancer

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Belgium, Spain, Italy, France, Germany, Ireland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer

Belgium, Italy, Hungary, Greece, Germany, Poland +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pik3ca Mutation trials by city

Pik3ca Mutation in Toronto Pik3ca Mutation in Vancouver Pik3ca Mutation in Montreal Pik3ca Mutation in Calgary Pik3ca Mutation in Edmonton Pik3ca Mutation in Ottawa Pik3ca Mutation in Winnipeg Pik3ca Mutation in Quebec City Pik3ca Mutation in Hamilton Pik3ca Mutation in Kitchener Pik3ca Mutation in London Pik3ca Mutation in Halifax Pik3ca Mutation in New York Pik3ca Mutation in Los Angeles Pik3ca Mutation in Chicago Pik3ca Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease